Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Vicore Pharma to Participate in Upcoming Healthcare Conferences

Stockholm, Sweden & Cambridge, Mass., September 1, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the following upcoming healthcare conferences:

  • Wells Fargo Healthcare Conference
    Location: Encore Boston Harbor, Boston, Mass.
    Format: 1×1 meetings
    Participation Date: Tuesday, September 8, 2026
    Participant: Ahmed Mousa, Chief Executive Officer
  • Cantor Global Healthcare Conference
    Location: Waldorf Astoria New York, New York, N.Y.
    Format: Fireside chat and 1×1 meetings
    Fireside Chat Date and Time: Friday, September 11, 2026, 9:45–10:15 AM ET
    Webcast: Link
    Participant: Ahmed Mousa, Chief Executive Officer

For more information, please contact:

Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma

Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Datum 2026-09-01, kl 08:00
Källa MFN